Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Title
Intervention Indication Therapeutic Area Year Actions
Vepdegestrant for previously treated locally advanced or metastatic ER+/HER2– breast cancer Vepdegestrant (ARV-471;PF-07850327) Breast cancer Breast Cancer 2023 View  |  Download
Venglustat for treating type 3 Gaucher disease after 1 therapy Venglustat Gaucher disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2023 View  |  Download
Venglustat for treating late onset GM2 gangliosidosis, GM1 gangliosidosis and other ultra-rare disease Venglustat GM1 gangliosidosis , GM2 gangliosidosis Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2023 View  |  Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2023 View  |  Download
Vanzacaftor / tezacaftor / deutivacaftor for the treatment of cystic fibrosis Deutivacaftor , Tezacaftor (VX-661) , Vanzacaftor Cystic fibrosis Genetic Disorders , Respiratory System 2023 View  |  Download
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children Ustekinumab (Stelara; CNTO 1275; CNTO-1275) Crohn's disease Gastroenterology , Immunology 2023 View  |  Download
Upadacitinib for treating giant cell arteritis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Giant cell arteritis Cardiovascular System 2023 View  |  Download
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of unresectable locally advanced or metastatic HER2-positive breast cancer Pertuzumab (Perjeta; R-1273) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2023 View  |  Download
Trastuzumab duocarmazine for third-line treatment of HER2-positive unresectable metastatic breast cancer Trastuzumab duocarmazine Breast cancer Breast Cancer 2023 View  |  Download
Trastuzumab deruxtecan neoadjuvant therapy for high-risk HER2-positive early stage breast cancer Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications